RxDoctor Payments Data

Clifford Myers, MD

Ophthalmology · Peoria, ILNPI 1356320253

Payments from drug & device makers

$759in general payments, 2019–2025

Across 21 payments — averaging $36.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$179
  • Glaukos Corporation$116
  • Alcon$89
  • Oyster Point Pharma, Inc.$74
  • Novartis$59
  • AbbVie$48
  • plus $194 from 7 others

What the payments were for

  • Food & beverage$759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$759 in reported general payments places this provider in the 40th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$148,943
Medicare patients
806
Services billed
1,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost104$33,224
RestasisCyclosporine16$21,037
RhopressaNetarsudil Mesylate30$12,383
RocklatanNetarsudil Mesylat/Latanoprost30$10,787
CombiganBrimonidine Tartrate/Timolol25$7,648
Brinzolamide23$4,227
Latanoprost405$3,813
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol40$2,971
Timolol Maleate26$1,554
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat103$1,263
Travoprost22$1,170
Prednisolone Acetate18$630
Dorzolamide Hcl18$333
Acyclovir13$318
Doxycycline Hyclate35$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$48$61,909145 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$12$23,17060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Peoria

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →